PTC/SB/88s (08-03.)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are req to a collection of information unless it contains a valid OMB control number.

Application Number		10534923	
Filing Date		2005-12-22	
First Named Inventor	First Named Inventor Shousheng He		
Art Unit			
Examiner Name			
Attorney Docket Numb	er	P16738-US2	
•			
	Filing Date First Named Inventor Art Unit Examiner Name	Filing Date First Named Inventor Shou	Filing Date 2005-12-22 First Named Inventor Shousheng He Art Unit Examiner Name

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue (	Date	Name of Pat of cited Docu	entee or Applicant ument	Releva	Columns,Lines want Passages or R Appear	
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ation	Name of Patentee or Applicant		Releva	es,Columns,Lines where evant Passages or Relevant ires Appear	
	1									
If you wisl	h to a	dd additional U.S. Publ	ished Ap	plication	citatio	n information p	please click the Ad	d buttor	1. Add	
				FOREI	GN PAT	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr	y Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,L where Relevant Passages or Rele Figures Appear	74
	1									
If you wis	h to a	dd additional Foreign F	atent Do	cument	citation	information p	lease click the Add	button	Add	
			NON	N-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), bublisher, city and/or country where publisher.							m Ts			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number		10534923		
		Filing Date		2005-12-22		
		First Named Inventor	First Named Inventor Shousheng He			
			Art Unit			
		ission and or or it ison	Examiner Name			
		Attorney Docket Number		P16738-US2		
	_					т-
	١.	ROLF JOHANSSON: *SYSTEM	MODELING AND IDENTIFIC	CATION	N* pages 200-207: Prentice Hall Englewood	١.

If you wish to add additional non-patent literature document citation information please click the Add button Add							
EXAMINER SIGNATURE							
Examiner Signature Date Considered							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a							

Cliffs. NJ 07632.

English language translation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of UBPTO Patent Documents at years USPTO.GGD or MPEP 901.04. I Enter office that issued the document, by the hor-letter code (WIPD Standard STJA). For Japanese patent documents, the includes not the year of the religion of the Emperor man procede the sensi number of the patent document. Affect document has a religional to select and a religional to the patent and control and the Vinder document with a religional to 15 life passits. I Septiment to piece a charge when the Vinder document with a religional to 15 life passits. I Septiment to 15 life passits.

URE ANT 1.99)	Application Number		10534923	
	Filing Date		2005-12-22	
	First Named Inventor Shou		usheng He	
	Art Unit			
	Examiner Name			
	Attorney Docket Numb	er	P16738-US2	

### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the	appropriate	selection(s

INFORMATION DISCLOS STATEMENT BY APPLICATION (Not for submission under 37 GFR

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

## OR

- That no item of information contained in the information disclosure statement was cited in a communication from a foreign patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement.
  - See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

## SIGNATURE

# A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael Cameron, #50298/	Date (YYYY-MM-DD)	2005-12-22
Name/Print	Michael Cameron	Registration Number	50298

This collection of information is required by 3T CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to fit field not by the USFTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Officer. U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.3.2311-450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.2331-4400.

#### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested to the process and/or examine your submission, which may related the process and/or examine your submission, which may related the process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
  - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.